The diagnosis interval influences risk factors of mortality in patients with co-existent active tuberculosis and lung cancer: a retrospective study
- PMID: 37817103
- PMCID: PMC10563245
- DOI: 10.1186/s12890-023-02674-3
The diagnosis interval influences risk factors of mortality in patients with co-existent active tuberculosis and lung cancer: a retrospective study
Abstract
Background: Previous studies reported that tuberculosis (TB) is associated with an increased risk of lung cancer or the survival and mortality of lung cancer. However, the impact of coexisting TB on the survival of lung cancer patients was controversial. We aimed to identify risk factors on the survival rate of patients with co-existent active TB and lung cancer.
Methods: One hundred seventy-three patients diagnosed with active TB and lung cancer from January 2016 to August 2021 in Shanghai pulmonary hospital were selected and divided into two groups (≤ 6 months, > 6 months) according to the diagnosis interval between active TB and lung cancer (the order of diagnosis is not considered). The clinical characteristics and survival were analyzed. Univariate and multivariate logistic regression analyses were used to identify the risk factors for overall survival (OS).
Results: One hundred seventy-three patients were diagnosed with lung cancer and active TB. The study population exhibited a median age of 64 years, with a majority of 81.5% being male, 58.0% of patients had a history of smoking. Among those involved, 93.6% had pulmonary TB, 91.9% were diagnosed with non-small cell lung cancer (NSCLC), 76.9% were Eastern Cooperative Oncology Group (ECOG) 0-2 and 12.7% were ECOG 3-4. We observed better survival in the > 6 months group compared with the ≤ 6 months group (hazard ratio [HR] 0.456, 95% confidence interval [CI]:0.234-0.889, P = 0.017). The 1-, 3-, and 5- year OS rates were 94.2%, 80.3%, and 77.6%, respectively, in the > 6 months group and 88.3%, 63.8%, and 58.5%, respectively, in the ≤ 6 months group. Surgery (HR 0.193, [95% CI, 0.038-0.097]; P = 0.046) and ECOG Performance Status (HR 12.866, [95% CI, 2.730-60.638]; P = 0.001) were independent prognostic factors in the > 6 months group.
Conclusions: Patients diagnosed with lung cancer and active TB for more than half a year have a significantly better prognosis than those diagnosed within half a year. ECOG Performance Status and surgery might possibly affect the outcomes of patients with co-existent active TB and lung cancer.
Keywords: Lung cancer; Survival; The diagnosis interval; Tuberculosis.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
The presence of old pulmonary tuberculosis is an independent prognostic factor for squamous cell lung cancer survival.J Cardiothorac Surg. 2013 May 6;8:123. doi: 10.1186/1749-8090-8-123. J Cardiothorac Surg. 2013. PMID: 23647947 Free PMC article.
-
Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.Asian Pac J Cancer Prev. 2014;15(6):2465-72. doi: 10.7314/apjcp.2014.15.6.2465. Asian Pac J Cancer Prev. 2014. PMID: 24761848
-
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.Oncologist. 2017 Sep;22(9):1075-1083. doi: 10.1634/theoncologist.2016-0331. Epub 2017 May 15. Oncologist. 2017. PMID: 28507206 Free PMC article.
-
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.Eur J Cancer. 2021 Jun;150:23-30. doi: 10.1016/j.ejca.2021.03.037. Epub 2021 Apr 18. Eur J Cancer. 2021. PMID: 33882375
-
[Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].Zhonghua Jie He He Hu Xi Za Zhi. 2024 Nov 12;47(11):1035-1041. doi: 10.3760/cma.j.cn112147-20240530-00299. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 39497387 Review. Chinese.
Cited by
-
Lung Cancer Screening: All That Glitters Is Not Gold.Cureus. 2024 Apr 7;16(4):e57783. doi: 10.7759/cureus.57783. eCollection 2024 Apr. Cureus. 2024. PMID: 38721157 Free PMC article.
-
Establishment and validation of a convenient and efficient screening tool for active pulmonary tuberculosis in lung cancer patients based on common parameters.Ther Adv Med Oncol. 2025 Jul 24;17:17588359251355058. doi: 10.1177/17588359251355058. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40727884 Free PMC article.
References
-
- World Health O . Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical